Cargando…

Plasmapheresis Reduces Mycophenolic Acid Concentration: A Study of Full AUC(0–12) in Kidney Transplant Recipients

Background: Mycophenolic acid (MPA), a crucial immunosuppressive drug, and plasmapheresis, an effective immunoreduction method, are simultaneously used for the management of various immune-related diseases, including kidney transplantation. While plasmapheresis has been proven efficient in removing...

Descripción completa

Detalles Bibliográficos
Autores principales: Piyasiridej, Sudarat, Townamchai, Natavudh, Udomkarnjananun, Suwasin, Vadcharavivad, Somratai, Pongpirul, Krit, Wattanatorn, Salin, Sirichindakul, Boonchoo, Avihingsanon, Yingyos, Tungsanga, Kriang, Eiam-Ong, Somchai, Praditpornsilpa, Kearkiat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947038/
https://www.ncbi.nlm.nih.gov/pubmed/31805655
http://dx.doi.org/10.3390/jcm8122084
_version_ 1783485477297324032
author Piyasiridej, Sudarat
Townamchai, Natavudh
Udomkarnjananun, Suwasin
Vadcharavivad, Somratai
Pongpirul, Krit
Wattanatorn, Salin
Sirichindakul, Boonchoo
Avihingsanon, Yingyos
Tungsanga, Kriang
Eiam-Ong, Somchai
Praditpornsilpa, Kearkiat
author_facet Piyasiridej, Sudarat
Townamchai, Natavudh
Udomkarnjananun, Suwasin
Vadcharavivad, Somratai
Pongpirul, Krit
Wattanatorn, Salin
Sirichindakul, Boonchoo
Avihingsanon, Yingyos
Tungsanga, Kriang
Eiam-Ong, Somchai
Praditpornsilpa, Kearkiat
author_sort Piyasiridej, Sudarat
collection PubMed
description Background: Mycophenolic acid (MPA), a crucial immunosuppressive drug, and plasmapheresis, an effective immunoreduction method, are simultaneously used for the management of various immune-related diseases, including kidney transplantation. While plasmapheresis has been proven efficient in removing many substances from the blood, its effect on MPA plasma levels remains unestablished. Objectives: To evaluate the full pharmacokinetics of MPA by measuring the area under the time–concentration curve (AUC(0–12)), which is the best indicator for MPA treatment monitoring after each plasmapheresis session, and to compare the AUC(0–12) measurements on the day with and on the day without plasmapheresis. Methods: A cross-sectional study was conducted in kidney transplantation recipients who were taking a twice-daily oral dose of mycophenolate mofetil (MMF, Cellcept(®)) and undergoing plasmapheresis at King Chulalongkorn Memorial Hospital, Bangkok, Thailand, during January 2018 and January 2019. The MPA levels were measured by an enzymatic method (Roche diagnostic(®)) 0, 1/2, 1, 2, 3, 4, 6, 8, and 12 h after MMF administration, for AUC(0–12) calculation on the day with and on the day without plasmapheresis sessions. Plasmapheresis was started within 4 h after administering the oral morning dose of MMF. Our primary outcome was the difference of AUC(0–12) between the day with and the day without plasmapheresis. Results: Forty complete AUC measurements included 20 measurements on the plasmapheresis day and other 20 measurements on the day without plasmapheresis in six kidney transplant patients. The mean age of the patients was 56.2 ± 20.7 years. All patients had received 1000 mg/day of MMF for at least 72 h before undergoing 3.5 ± 1.2 plasmapheresis sessions. The mean AUC on the day with plasmapheresis was lower than that on the day without plasmapheresis (28.22 ± 8.21 vs. 36.79 ± 10.29 mg × h/L, p = 0.001), and the percentage of AUC reduction was 19.49 ± 24.83%. This was mainly the result of a decrease in AUC(0–4) of MPA (23.96 ± 28.12% reduction). Conclusions: Plasmapheresis significantly reduces the level of full AUC(0–12) of MPA. The present study is the first to measure the full AUC(0–12) in MPA-treated patients undergoing plasmapheresis. Our study suggests that a supplementary dose of MPA is necessary for patients undergoing plasmapheresis.
format Online
Article
Text
id pubmed-6947038
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69470382020-01-13 Plasmapheresis Reduces Mycophenolic Acid Concentration: A Study of Full AUC(0–12) in Kidney Transplant Recipients Piyasiridej, Sudarat Townamchai, Natavudh Udomkarnjananun, Suwasin Vadcharavivad, Somratai Pongpirul, Krit Wattanatorn, Salin Sirichindakul, Boonchoo Avihingsanon, Yingyos Tungsanga, Kriang Eiam-Ong, Somchai Praditpornsilpa, Kearkiat J Clin Med Article Background: Mycophenolic acid (MPA), a crucial immunosuppressive drug, and plasmapheresis, an effective immunoreduction method, are simultaneously used for the management of various immune-related diseases, including kidney transplantation. While plasmapheresis has been proven efficient in removing many substances from the blood, its effect on MPA plasma levels remains unestablished. Objectives: To evaluate the full pharmacokinetics of MPA by measuring the area under the time–concentration curve (AUC(0–12)), which is the best indicator for MPA treatment monitoring after each plasmapheresis session, and to compare the AUC(0–12) measurements on the day with and on the day without plasmapheresis. Methods: A cross-sectional study was conducted in kidney transplantation recipients who were taking a twice-daily oral dose of mycophenolate mofetil (MMF, Cellcept(®)) and undergoing plasmapheresis at King Chulalongkorn Memorial Hospital, Bangkok, Thailand, during January 2018 and January 2019. The MPA levels were measured by an enzymatic method (Roche diagnostic(®)) 0, 1/2, 1, 2, 3, 4, 6, 8, and 12 h after MMF administration, for AUC(0–12) calculation on the day with and on the day without plasmapheresis sessions. Plasmapheresis was started within 4 h after administering the oral morning dose of MMF. Our primary outcome was the difference of AUC(0–12) between the day with and the day without plasmapheresis. Results: Forty complete AUC measurements included 20 measurements on the plasmapheresis day and other 20 measurements on the day without plasmapheresis in six kidney transplant patients. The mean age of the patients was 56.2 ± 20.7 years. All patients had received 1000 mg/day of MMF for at least 72 h before undergoing 3.5 ± 1.2 plasmapheresis sessions. The mean AUC on the day with plasmapheresis was lower than that on the day without plasmapheresis (28.22 ± 8.21 vs. 36.79 ± 10.29 mg × h/L, p = 0.001), and the percentage of AUC reduction was 19.49 ± 24.83%. This was mainly the result of a decrease in AUC(0–4) of MPA (23.96 ± 28.12% reduction). Conclusions: Plasmapheresis significantly reduces the level of full AUC(0–12) of MPA. The present study is the first to measure the full AUC(0–12) in MPA-treated patients undergoing plasmapheresis. Our study suggests that a supplementary dose of MPA is necessary for patients undergoing plasmapheresis. MDPI 2019-12-01 /pmc/articles/PMC6947038/ /pubmed/31805655 http://dx.doi.org/10.3390/jcm8122084 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Piyasiridej, Sudarat
Townamchai, Natavudh
Udomkarnjananun, Suwasin
Vadcharavivad, Somratai
Pongpirul, Krit
Wattanatorn, Salin
Sirichindakul, Boonchoo
Avihingsanon, Yingyos
Tungsanga, Kriang
Eiam-Ong, Somchai
Praditpornsilpa, Kearkiat
Plasmapheresis Reduces Mycophenolic Acid Concentration: A Study of Full AUC(0–12) in Kidney Transplant Recipients
title Plasmapheresis Reduces Mycophenolic Acid Concentration: A Study of Full AUC(0–12) in Kidney Transplant Recipients
title_full Plasmapheresis Reduces Mycophenolic Acid Concentration: A Study of Full AUC(0–12) in Kidney Transplant Recipients
title_fullStr Plasmapheresis Reduces Mycophenolic Acid Concentration: A Study of Full AUC(0–12) in Kidney Transplant Recipients
title_full_unstemmed Plasmapheresis Reduces Mycophenolic Acid Concentration: A Study of Full AUC(0–12) in Kidney Transplant Recipients
title_short Plasmapheresis Reduces Mycophenolic Acid Concentration: A Study of Full AUC(0–12) in Kidney Transplant Recipients
title_sort plasmapheresis reduces mycophenolic acid concentration: a study of full auc(0–12) in kidney transplant recipients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947038/
https://www.ncbi.nlm.nih.gov/pubmed/31805655
http://dx.doi.org/10.3390/jcm8122084
work_keys_str_mv AT piyasiridejsudarat plasmapheresisreducesmycophenolicacidconcentrationastudyoffullauc012inkidneytransplantrecipients
AT townamchainatavudh plasmapheresisreducesmycophenolicacidconcentrationastudyoffullauc012inkidneytransplantrecipients
AT udomkarnjananunsuwasin plasmapheresisreducesmycophenolicacidconcentrationastudyoffullauc012inkidneytransplantrecipients
AT vadcharavivadsomratai plasmapheresisreducesmycophenolicacidconcentrationastudyoffullauc012inkidneytransplantrecipients
AT pongpirulkrit plasmapheresisreducesmycophenolicacidconcentrationastudyoffullauc012inkidneytransplantrecipients
AT wattanatornsalin plasmapheresisreducesmycophenolicacidconcentrationastudyoffullauc012inkidneytransplantrecipients
AT sirichindakulboonchoo plasmapheresisreducesmycophenolicacidconcentrationastudyoffullauc012inkidneytransplantrecipients
AT avihingsanonyingyos plasmapheresisreducesmycophenolicacidconcentrationastudyoffullauc012inkidneytransplantrecipients
AT tungsangakriang plasmapheresisreducesmycophenolicacidconcentrationastudyoffullauc012inkidneytransplantrecipients
AT eiamongsomchai plasmapheresisreducesmycophenolicacidconcentrationastudyoffullauc012inkidneytransplantrecipients
AT praditpornsilpakearkiat plasmapheresisreducesmycophenolicacidconcentrationastudyoffullauc012inkidneytransplantrecipients